GTC
ITCI

Ghost Tree Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ghost Tree Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$3.46M – 84
2024
Q1 		$3.46M Buy
+50,000
New +$3.44M 0.96% 35
2019
Q1 		– Sell
-79,400
Closed -$904K – 45
2018
Q4 		$904K Buy
+79,400
New +$1.28M 0.33% 36
2017
Q3 		– Sell
-500,000
Closed -$6.21M – 74
2017
Q2 		$6.21M Buy
+500,000
New +$5.8M 1.29% 31

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ghost Tree Capital's ITCI Position: Q3 2024 in Review

Ghost Tree Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2024, closing a stake of 10,000 shares — an estimated $685K sold.

Ghost Tree Capital first reported a position in ITCI in Q2 2016 and held it in 5 quarters. The position peaked at $4.66M in Q2 2016. 354 funds tracked by Wall St. Rank hold ITCI as of Q3 2024.

  • Ghost Tree Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2024 after selling out during the quarter.
  • Ghost Tree Capital sold 10,000 Intra-Cellular Therapies Inc. shares in Q3 2024, an estimated $685K.
  • Ghost Tree Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 5 quarters.
  • Ghost Tree Capital's Intra-Cellular Therapies Inc. position peaked at $4.66M in Q2 2016.
  • 354 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.